Search research articles
Contact Us
Filters
Showing results (51-60 of 104) with videos related to
Page
of 11
Sort By:
Pediatric Blood & Cancer
|
January 17, 2009
Reduced risk of secondary leukemia with fewer cycles of dose-intensive induction chemotherapy in patients with neuroblastoma
Brian H Kushner, Kim Kramer, Shakeel Modak, et al.
International Journal of Cancer
|
January 10, 2026
Naxitamab with novel scheduling and stepped-up dosing of GM-CSF plus vaccine, but no myeloablative therapy for patients with high-risk neuroblastoma in first complete remission
Brian H Kushner, Charlie White, Audrey Mauguen, et al.
International Journal of Radiation Oncology, Biology, Physics
|
May 12, 2009
Hyperfractionated low-dose (21 Gy) radiotherapy for cranial skeletal metastases in patients with high-risk neuroblastoma
Brian H Kushner, Nai-Kong V Cheung, Christopher A Barker, et al.
Pediatric Blood & Cancer
|
November 2, 2007
Transient sialoadenitis: a complication of 131I-metaiodobenzylguanidine therapy
Shakeel Modak, Neeta Pandit-Taskar, Brian H Kushner, et al.
International Journal of Cancer
|
August 1, 2022
Immunotherapy with anti-G<sub>D2</sub> monoclonal antibody in infants with high-risk neuroblastoma
Brian H Kushner, Shakeel Modak, Kim Kramer, et al.
Research Square
|
March 11, 2024
Feasibility of safe outpatient treatment in pediatric patients following intraventricular radioimmunotherapy with 131I-omburtamab for leptomeningeal disease
Kavya Prasad, Brian E Serencsits, Bae P Chu, et al.
International Journal of Radiation Oncology, Biology, Physics
|
March 9, 2010
Whole neuraxis irradiation to address central nervous system relapse in high-risk neuroblastoma
Victoria J Croog, Kim Kramer, Nai-Kong V Cheung, et al.
EJNMMI Research
|
July 31, 2024
Feasibility of safe outpatient treatment in pediatric patients following intraventricular radioimmunotherapy with <sup>131</sup>I-omburtamab for leptomeningeal disease
Kavya Prasad, Brian E Serencsits, Bae P Chu, et al.
Journal of Neuro-Oncology
|
April 11, 2022
Quantifying intraventricular drug delivery utilizing programmable ventriculoperitoneal shunts as the intraventricular access device
Sheila S McThenia, Neeta Pandit-Taskar, Milan Grkovski, et al.
Cancers
|
December 24, 2021
Phase I Trial of Oral Yeast-Derived β-Glucan to Enhance Anti-GD2 Immunotherapy of Resistant High-Risk Neuroblastoma
Fiorella Iglesias Cardenas, Audrey Mauguen, Irene Y Cheung, et al.
Page
of 11
Search research articles
Search
Showing results (51-60 of 104) with videos related to
Sort By:
Page
of 11
Pediatric Blood & Cancer
|
January 17, 2009
Reduced risk of secondary leukemia with fewer cycles of dose-intensive induction chemotherapy in patients with neuroblastoma
Brian H Kushner, Kim Kramer, Shakeel Modak, et al.
International Journal of Cancer
|
January 10, 2026
Naxitamab with novel scheduling and stepped-up dosing of GM-CSF plus vaccine, but no myeloablative therapy for patients with high-risk neuroblastoma in first complete remission
Brian H Kushner, Charlie White, Audrey Mauguen, et al.
International Journal of Radiation Oncology, Biology, Physics
|
May 12, 2009
Hyperfractionated low-dose (21 Gy) radiotherapy for cranial skeletal metastases in patients with high-risk neuroblastoma
Brian H Kushner, Nai-Kong V Cheung, Christopher A Barker, et al.
Pediatric Blood & Cancer
|
November 2, 2007
Transient sialoadenitis: a complication of 131I-metaiodobenzylguanidine therapy
Shakeel Modak, Neeta Pandit-Taskar, Brian H Kushner, et al.
International Journal of Cancer
|
August 1, 2022
Immunotherapy with anti-G<sub>D2</sub> monoclonal antibody in infants with high-risk neuroblastoma
Brian H Kushner, Shakeel Modak, Kim Kramer, et al.
Research Square
|
March 11, 2024
Feasibility of safe outpatient treatment in pediatric patients following intraventricular radioimmunotherapy with 131I-omburtamab for leptomeningeal disease
Kavya Prasad, Brian E Serencsits, Bae P Chu, et al.
International Journal of Radiation Oncology, Biology, Physics
|
March 9, 2010
Whole neuraxis irradiation to address central nervous system relapse in high-risk neuroblastoma
Victoria J Croog, Kim Kramer, Nai-Kong V Cheung, et al.
EJNMMI Research
|
July 31, 2024
Feasibility of safe outpatient treatment in pediatric patients following intraventricular radioimmunotherapy with <sup>131</sup>I-omburtamab for leptomeningeal disease
Kavya Prasad, Brian E Serencsits, Bae P Chu, et al.
Journal of Neuro-Oncology
|
April 11, 2022
Quantifying intraventricular drug delivery utilizing programmable ventriculoperitoneal shunts as the intraventricular access device
Sheila S McThenia, Neeta Pandit-Taskar, Milan Grkovski, et al.
Cancers
|
December 24, 2021
Phase I Trial of Oral Yeast-Derived β-Glucan to Enhance Anti-GD2 Immunotherapy of Resistant High-Risk Neuroblastoma
Fiorella Iglesias Cardenas, Audrey Mauguen, Irene Y Cheung, et al.
Page
of 11